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The magnitude of drug interactions between azole antifungals and
immunosuppressants is drug and patient specific and depends on the potency
of the azole inhibitor involved, the resulting plasma concentrations of each
drug, the drug formulation, and interpatient variability.  Many factors
contribute to variability in the magnitude and clinical significance of drug
interactions between an immunosuppressant such as cyclosporine, tacrolimus,
or sirolimus and an antifungal agent such as ketoconazole, fluconazole,
itraconazole, voriconazole, or posaconazole.  By bringing similarities and
differences among these agents and their potential interactions to clinicians’
attention, they can appreciate and apply these findings in a individualized
patient approach rather than follow only the one-size-fits-all dosing
recommendations suggested in many tertiary references.  Differences in
metabolism and in the inhibitory potency of cytochrome P450 3A4 and P-
glycoprotein influence the onset, magnitude, and resolution of drug
interactions and their potential effect on clinical outcomes.  Important issues
are the route of administration and the decision to preemptively adjust
dosages versus intensive monitoring with subsequent dosage adjustments.
We provide recommendations for the concomitant use of these agents,
including suggestions regarding contraindicated combinations, those best
avoided, and those requiring close monitoring of drug dosages and plasma
concentrations.
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Conclusion
The frequency of infections and mortality due
to mycotic disease in the United States has
increased dramatically over the past 2 decades.
Among infectious disease–related deaths, those
due to mycoses increased from being tenth most
common in 1980 to seventh most common in
1997.1 Invasive fungal infections particularly
affect immunocompromised patients, including
those with cancer, acquired immunodeficiency
syndrome, or solid organ or bone marrow
transplants, as well as certain high-risk patients
with burns or critical conditions and neonates
born prematurely.2, 3
Fungal infections occur in 11–28% of
transplant recipients.  Although the highest
frequency is reported in liver transplant
recipients, 10–15% of patients undergoing bone
marrow transplantation become infected, with a
mortality rate of 60–75%.4 The interaction of
three factors largely determine the high
frequency of fungal infections in transplant
recipients:  technical and/or anatomic abnor-
malities, intensity of environmental exposure,
and the patient’s net state of immuno-
suppression.3
Fungal infections associated with immuno-
suppression-related, T cell–mediated defects
include mucosal candidiasis, cryptococcosis, and
mucormycosis, whereas neutropenia-related
fungal infections include aspergillosis and
disseminated candidiasis.4 These infections tend
to occur early after transplantation, and their
frequency decreases over time.5 In patients
undergoing solid organ transplantation, the 1–6-
month period after the procedure is highlighted
by the emergence of opportunistic infections,
such as histoplasmosis, coccidioidomycosis,
blastomycosis and Pneumocystis carinii
(Pneumocystis jiroveci) pneumonia.6 Patients
receiving bone marrow transplantation are at
highest risk for fungal infections during the
preengraftment period, which lasts from the day
bone marrow or stem cells are infused (day 0) to
approximately day 30 after transplantation.4
Given the high mortality rate associated with
invasive mycoses in solid organ or bone marrow
transplantation, effective prophylaxis and
treatment of such infections are worthy goals.
Although appropriate antifungal agents and their
dosages for treating opportunistic mycoses have
been defined, decisions regarding the modes of
drug delivery, the patients who should receive
antifungal prophylaxis, the duration of treatment
or prophylaxis, and the potential for the
emergence of resistant fungi remain subjects of
uncertainty and controversy.7
Investigators have described the need to design
a therapeutic prescription for transplant
recipients that prevents and treats the two major
barriers to successful transplantation:  rejection
and infection.  The therapeutic prescription
consists of an immunosuppressive program and
an antimicrobial program; changes in the
intensity and nature of one program obligate
changes in the other.  The technical and/or
anatomic consequences of transplantation, the
time course of infection after transplantation, and
the possibility of drug interactions with the
immunosuppressive program greatly influence
the use of antimicrobials in transplant recipients.8
Drug interactions between immunosuppres-
sants and azoles are discussed elsewhere.9–12 Our
objective was to describe certain studies to
illustrate similarities and differences among these
interactions so that clinicians can appreciate and
apply these findings in an individualized patient
approach rather than follow only the one-size-
fits-all dosing recommendations suggested in
many tertiary references.  Clinicians must be
aware of the combined influence of drug
transport and metabolic routes on the likelihood
and magnitude of drug interactions.  Because
data are not available for all potential drug-drug
combinations, a thorough understanding of the
principles underlying drug interactions is crucial
to anticipate potential interactions with new or
existing agents used in the clinical setting.
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Mechanisms of Drug Interactions Mediated by
Cytochrome P450 Enzymes and Transport
Proteins
Metabolism Involving the Cytochrome P450
Enzyme System
A thorough understanding of the mechanisms
of drug interactions provides clinicians the ability
to predict such interactions and to devise
strategies to minimize or avoid those of greatest
clinical significance.13 Drug interactions can be
categorized as pharmacodynamic or pharmaco-
kinetic.  Pharmacodynamic interactions include
additive, synergistic, or antagonistic interactions
that can affect efficacy or toxicity.  Pharmaco-
kinetic interactions result when one drug alters
the absorption, distribution, metabolism, or
excretion of another drug.
Inhibition or induction of hepatic and
extrahepatic cytochrome P450 (CYP) enzymes is
the most common mechanism of drug
interactions.13 The major site of drug metabolism
is the liver, where two types of reactions occur.
In phase I reactions catalyzed by CYP enzymes,
oxidation of a parent drug yields a more polar,
hydrophilic moiety that may be pharmaco-
logically active or inactive.  In phase II reactions,
which CYP enzymes do not mediate, conjugation
of the parent drug or previously oxidized drug
yields a hydrophilic moiety that is excreted in the
feces or urine more readily than the parent
drug.14
Cytochrome P450 enzymes are heme proteins
that catalyze phase I metabolism of many
endogenous substrates, including steroids, fatty
acids, prostaglandins, bile acids, and xenobiotics
(including drugs, carcinogens, environmental
pollutants, and many synthetic chemicals).14
These enzymes are found in the smooth
endoplasmic reticulum of liver hepatocytes and
in the villous columnar epithelium of the
jejunum, lungs, kidney, and brain.  More than 40
CYP enzymes have been identified in humans.
Of these, CYP3A4, CYP2D6, CYP1A2, CYP2C9,
CYP2C19, and CYP2E1 are responsible for
metabolizing nearly all clinically useful drugs.15
The observation that CYP3A4 metabolizes
nearly 50% of all clinically used drugs and
endogenous steroids may explain why CYP3A4,
among the CYP enzymes, is most often involved
in drug metabolism and drug interactions.16 This
enzyme accounts for 29% and 70% of the total
human hepatic and gastrointestinal tract CYP
enzymes, respectively, affecting both presystemic
and systemic drug distribution.14, 17 This first-
pass elimination results in variable (often low)
oral bioavailability of CYP3A4-metabolized
drugs.
An important characteristic of CYP3A is its
large interindividual variability in activity, which
reflects a genetic effect combined with modula-
tion by environmental factors.  The inhibition
and induction of enzymes often substantially
increases this variability.  Hepatic CYP3A4 varies
at least 20-fold, and enteric CYP3A4 varies 10-
fold among individuals.  However, the CYP3A4
content of each site appears to be regulated
independently.  Thus, one patient might have
high CYP3A4 activity in the liver and low
CYP3A4 activity in the intestine, whereas another
patient has the opposite activities; the liver is the
major site of drug metabolism in the first patient,
whereas the intestine is the major site in the
second.18 Relative contributions of hepatic and
enteric metabolism can be estimated separately
by determining differences in drug clearance after
oral and intravenous administration of a
CYP3A4-metabolized drug.17
The CYP group of enzymes can be highly
substrate specific and therefore capable of
metabolizing only a few substrates, or they may
be poorly specific and capable of metabolizing a
broad range of substrates.  The degree of enzyme
specificity greatly affects the outcome of its
inhibition.  The broader the enzyme specificity,
the more drug interactions its inhibition is likely
to elicit.  To predict, evaluate, and manage such
drug interactions, clinicians must first identify
the enzymes responsible for each agent’s
metabolism.  Then, they must consider the
dosages and timing of administration of the
drugs in question, the duration of therapy, the
baseline and steady state concentrations, the
therapeutic index of each agent, and the potential
for interindividual variability in pharmacokinetic
variables, including absorption, distribution,
metabolism, and elimination.13
Substrates, Inducers, and Inhibitors
Drugs can be substrates, inducers, and inhibi-
tors of CYP enzymes.  Substrates are moieties
that undergo metabolism by one or more CYP
enzymes.  Inducers increase the amount or
activity of a CYP enzyme.  By contrast, inhibitors
decrease the amount or activity of the enzyme.
Enzyme inducers and inhibitors produce their
effects in a dose- and concentration-dependent
manner; within a range, high doses or concen-
trations of drugs generally increase induction or
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inhibition.  Inducers and inhibitors differ in the
onset and duration of their effects on CYP
enzymes.  Although maximum enzyme induction
is generally achieved over approximately 2
weeks, enzyme inhibition can be observed
immediately after the administration of the first
dose of an inhibitor drug.14–16 Limited data are
available regarding the duration of enzyme
inhibition or induction after inducers or
inhibitors are discontinued; however, the half-
lives and protein binding of inducers and
inhibitors are factors.
Enzyme induction refers to an increase in
enzymatic activity due to increased production of
the enzyme (by means of enhanced transcription
and translation) or due to a reduction in the
natural rate of its breakdown.  The CYP enzymes
that are known to be inducible are CYP1A2,
CYP2C9, CYP2E1, and CYP3A4.19 Unlike CYP
inhibitors, which have an immediate effect,
enzyme induction is gradual.  Once an enzyme is
induced, removal of the inducing agent
eventually results in normalization of enzyme
activity.  Common inducers are phenytoin,
carbamazepine, rifampin, and ethanol.  As can be
predicted, these agents often increase the
metabolism of the other CYP substrates,
potentially resulting in therapeutic failures.20, 21
In general, for CYP3A4 substrates (e.g.,
immunosuppressants) with low oral bioavail-
ability (high presystemic or first-pass elimi-
nation), administration of a single dose of a
CYP3A4 inhibitor substantially increases the area
under the plasma concentration–time curve
(AUC) for the substrate.  By contrast, concomitant
administration of a single dose of a CYP3A4
inhibitor with a CYP3A4 substrate with high oral
bioavailability does not produce a large effect.
However, repeat administration of both may
cumulatively increase plasma substrate concen-
trations, and a clinically significant interaction
may occur only during steady-state conditions.17
An inhibitor can be classified as competitive or
noncompetitive.  By mimicking the substrate, a
competitive inhibitor competes for binding to the
active site of an enzyme.  For a competitive
inhibitor to fully inhibit a site, high concen-
trations are needed.  The higher the concentration,
the stronger the inhibition.  The clinical
significance of drug interactions resulting from
competitive inhibition depends on the concen-
tration of the inhibitor achieved at the site of
inhibition, the relative doses of the inhibitor and
the substrate, the relative bioavailability, the
relative affinity constants of the inhibitor and
substrate (i.e., how tightly they bind to the site),
the interindividual variability, and the therapeutic
indices of the drugs.9 At equimolar concentrations,
ketoconazole is the most potent CYP3A4 inhibi-
tor among the azoles, followed by itraconazole,
voriconazole, and fluconazole.
A noncompetitive inhibitor binds to a location
on the enzyme other than the active site, altering
its conformation so that the active site is no
longer fully functional.  Only minimal amounts
of a noncompetitive inhibitor are needed for
inhibition to be effective.  Table 1 summarizes
the metabolism of azoles, the CYP enzymes
involved, and the type and relative potency of
inhibition.22–25
Genetic Polymorphism
A major cause of drug metabolism and
subsequent drug effects is genetic polymorphism,
in particular CYP2D6, CYP2C9, and CYP2C19.
The distribution of these enzymes in the
population is polymodal, as determined by
genetic polymorphism.  Although CYP3A4 drug-
metabolizing activity varies widely among
individuals, notable polymorphisms have not
been identified.17
Active Transport of Azoles and
Immunosuppressants
In addition to CYP enzymes, active trans-
porters (e.g., P-glycoprotein [P-gp]), and the
organic anion–transporting polypeptides (e.g.,
hepatic canalicular efflux transporter MRP2) play
an important role in drug interactions.  Active
drug transporters play a key role in regulating
access of drugs to the drug-metabolizing enzymes
and controlling drug concentrations in entero-
cytes and hepatocytes.
A plasma membrane–associated glycoprotein,
P-gp is a member of the adenosine 5′- triphos-
phate (ATP)–binding cassette transporter
superfamily and a product of the multidrug
resistance 1 (MDR1) gene.  Although variably
expressed in the population, P-gp is present at
high levels in the liver, kidney, pancreas, small
intestine, colon, and adrenal gland, as well as in
the capillary endothelium of the brain and testes.
This glycoprotein functions as an ATP-dependent
efflux pump that excretes xenobiotics into bile,
gastrointestinal tract, and urine and that prevents
access to the central nervous system by limiting
transport across the blood-brain barrier.  These
actions lower plasma and cerebrospinal fluid
concentrations of xenobiotics, suggesting that P-
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gp has a role in defense against xenobiotics.15 In
the gastrointestinal tract, P-gp is located in the
brush border on the apical (luminal) surface of
mature enterocytes.  The colon has the highest P-
gp expression, and the stomach and jejunum-
ileum, the lowest.26
Enzyme-Transporter Cooperativity
Both P-gp and CYP3A4 share some substrate
overlap and are colocalized in the small intestine,
where they form a cooperative barrier that limits
the oral bioavailability of xenobiotics and drugs,
such as immunosuppressants.  Substrates (e.g.,
immunosuppressants) for P-gp and CYP3A4
entering an enterocyte may be absorbed directly
into the systemic circulation, metabolized by
CYP3A4 in the enterocyte, or secreted back into
the intestinal lumen by P-gp.  Drug pumped back
into the lumen may be reabsorbed at a distal site
and exposed again to any of the three fates just
described.18
For dual-substrate drugs, repeated pumping
out of the enterocyte by P-gp limits and regulates
their access to CYP3A4 metabolism and prevents
high drug concentrations in the enterocyte from
overwhelming the enzyme.  Therefore, the two
proteins function in concert to reduce the
intracellular concentration of xenobiotics.22, 27
Coordinate upregulation of CYP3A was
demonstrated in a cell culture model in response
to some xenobiotics.  However, other drugs have
caused selective upregulation of P-gp expression.12
Despite this shared functionality, no correlation
was found between intrasubject enterocyte P-gp
levels and CYP3A4 in the small intestine and/or
liver.  Moreover, CYP3A4 and P-gp do not appear
to be coordinately regulated.28
The uptake of P-gp substrates can become
saturated.  When this occurs or when P-gp is
inhibited, passive diffusion becomes the rate-
limiting step in absorption.  Therefore, increased
doses of cyclosporine can increase the rate and
extent of drug absorption.  Drugs with high
partition coefficients (i.e., highly lipophilic
agents) can diffuse rapidly.  The azoles, which are
P-gp substrates, differ in their lipophilicity.
Inhibition or saturation of P-gp has greatest effect
on the oral bioavailability of water-soluble agents
(e.g., fluconazole) because relatively lipophilic
agents (e.g., itraconazole) can rapidly diffuse
across the enterocyte.
Inhibition Constant
Clinical observations suggest that azoles have
various potencies with respect to their ability to
inhibit CYP3A4 and P-gp.29 Determining the in
vitro inhibition constant, Ki, which quantifies the
molecular interaction and inhibitory potency of
an agent, assists in predicting the magnitude of in
vivo drug interactions.  For a specific enzyme, Ki
is a constant that is largely independent of
substrate identity.  This constant can be used to
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Table 1.  Metabolism of Azoles and Immunosuppressants22–25
CYPa Inhibition of CYP3A4 P-glycoprotein
Agent Substrate Inhibitor Potency Type Substrate Inhibitor
Ketoconazole 3A4 3A4, 2C19 ++++ Competitive, Yes Yes
noncompetitive
Fluconazole 3A4 2C9, 2C19 + Noncompetitive, Yes No
mixed
Itraconazole 3A4 3A4 +++ Competitive Yes Yes
Hydroxyitraconazole 3A4? 3A4 ND Competitive ND ND
Ketoitraconazole 3A4 3A4 ND ND ND ND
N-desalkylitraconazole 3A4 3A4 ND ND ND ND
Voriconazole 3A4 3A4, 2C9, ++ to +++ Competitive, ND ND
2C19 noncompetitive
Posaconazole NDb 3A4 +++c ND Yes Yes
Cyclosporine 3A4 3A4 ND Competitive Yes Yes
Tacrolimus 3A4 ND ND ND Yes Yes
13-O-desmethyltacrolimus ND ND ND ND Yes Yes
Sirolimus 3A4 ND ND Competitive Yes Yes
Everolimus 3A4 ND ND ND Yes Yes
CYP = cytochrome P450; ND = no data.
aCYP enzyme involved in the metabolism of the azole.
bTo date, none have been identified; does not inhibit CYP3A4.
cBased on limited data.
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predict enzyme behavior over a wide range of
substrate and enzyme concentrations and,
theoretically, to compare the inhibition potency
of different drugs.30 As Ki decreases, the potency
of the inhibitor increases exponentially.
The most potent reversible CYP3A inhibitors,
which include azole antifungal agents and human
immunodeficiency virus protease inhibitors, have
Ki values below 1 µmol.  Clinically significant
inhibition is uncommon for compounds with
values above 75–100 µmol because sufficiently
high concentrations are not clinically achieved.31,
32 For example, ketoconazole and fluconazole
are inhibitors of human hepatic and intestinal
CYP3A4.  However, ketoconazole is a more
potent inhibitor than fluconazole, with mean ±
SD Ki values of 14.9 ± 6.7 and 17.0 ± 7.9 nmol
for hepatic and intestinal microsomes, respec-
tively; by contrast, Ki values for fluconazole are
10.7 ± 4.2 and 10.4 ± 2.9 µmol, respectively.
These data reflect a 1000-fold difference in the
magnitude of  CYP3A4 inhibition.33 An
extensive review on the use of inhibitory
constants to evaluate the potential for drug-drug
interactions has been published.34
The practice of using in vitro–in vivo scaling
procedures to predict the effect of the
coadministration of CYP inhibitory agents on in
vivo drug interactions has many limitations.
First, because in vitro studies are performed in
human or animal preparations of liver
microsomes, they do not reflect the possible
contributions of extrahepatic CYPs and P-gp.17
Second, concentrations of the inhibitor at the
active site of the enzyme in vitro may not mirror
concentrations in vivo.35 Third, in vitro
experiments are usually conducted in media that
are devoid of plasma proteins and that do not
mimic the in vivo setting with respect to pH,
ionic strength, or protein binding, all of which
can affect enzyme activity.30 Finally, metabolites
of the inhibitor may contribute to overall
inhibitory effects on the enzyme.  In general, the
overall limitation is that a given concentration of
an inhibitor is more potent in vivo than it is in
vitro.35 As a result, human data should be
obtained whenever possible.17 However, in vitro
drug interactions can be used as screening tools
that provide the rationale for further, in-depth
examination of the interaction in human clinical
trials.
Metabolism of Azoles
Currently available azoles inhibit the fungal
CYP3A4-dependent enzyme lanosterol 14-a-
demethylase.  They hinder the synthesis of
ergosterol, the major sterol component of fungal
plasma membranes, resulting in altered membrane
fluidity and inhibition of fungal growth and
replication.36 Early azoles, such as ketoconazole,
are poorly selective in the inhibition of fungal
versus mammalian CYP3A4.  As a result, they
can cross-inhibit mammalian CYP3A4, leading to
drug interactions with other CYP3A4-metabolized
drugs and to adverse effects (e.g., gynecomastia,
adrenocortical insufficiency) due to the
inhibition of CYP3A4-mediated metabolism of
human steroid hormones.36, 37 New azoles have
enhanced selectivity for fungal versus
mammalian CYP3A4.  As a consequence, they
have improved toxicity and drug-interaction
profiles.36
The lipophilicity and lack of aqueous solubility
of azoles influence the likelihood of their inter-
acting with immunosuppressants.  Ketoconazole,
itraconazole, voriconazole, and posaconazole are
more lipophilic than fluconazole and require
extensive oxidative CYP metabolism to
hydrophilic metabolites in order to be eliminated
from the body.36, 38, 39 Itraconazole, the most
lipophilic and water-insoluble azole, is prone to
enzymatic and transporter-mediated interactions
in the intestine, liver, and kidney that interfere
with the absorption and elimination of it and
other drugs.
More than 30 metabolites have been proposed
for itraconazole, only one of which, hydroxy-
itraconazole, has been studied in humans.  The
biotransformation of itraconazole is complex and
incompletely understood; however, CYP3A4
catalyzes most, if not all, of its metabolism.  In
addition to hydroxyitraconazole, which is formed
primarily in the intestine by CYP3A4, itraconazole
and hydroxyitraconazole are converted to
ketoitraconazole.  In addition, CYP3A4 catalyzes
the conversion of ketoitraconazole, and possibly
itraconazole and hydroxyitraconazole, to N-
desalkylitraconazole.  Hydroxyitraconazole
possesses antifungal activity similar to that of
itraconazole, but it circulates at increased plasma
concentrations.  Itraconazole is a relatively
potent inhibitor of CYP3A4 in vitro.  Recent in
vitro studies demonstrated that hydroxyitra-
conazole, ketoitraconazole, and N-desalkylitra-
conazole are CYP3A4 inhibitors at least as potent
as itraconazole; therefore, they may contribute
substantially to the inhibition of CYP3A4
observed clinically.  The long half-life of
itraconazole and its pharmacologically active
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metabolites prolong the inhibitory effects on
CYP3A4 metabolism of immunosuppressants.38, 39
Voriconazole, which is lipophilic and which
has limited water solubility, is well absorbed
orally and less prone than other drugs to presys-
temic interactions in the intestine.  Voriconazole
drug interactions are dose dependent.  Because it
has unpredictable nonlinear pharmacokinetics,
its drug interactions are difficult to predict and
manage.  The hepatic biotransformation of
voriconazole is fairly complex and involves
CYP2C19, CYP3A4, and CYP2C9.  The principle
N-oxide metabolite of voriconazole is formed by
CYP2C19 and CYP3A4 and, to some extent,
CYP2C9.38, 39 Two CYPs involved in voriconazole
metabolism, CYP2C19 and CYP2C9, exhibit
genetic polymorphism.  Variability in the
CYP2C19 genotype accounts for approximately
30% of the overall between-subject variability in
voriconazole pharmacokinetics.40
Homozygous poor metabolizers have the
highest plasma concentrations of voriconazole,
followed by heterozygous extensive metabolizers,
then homozygous extensive metabolizers.  After
oral and intravenous dosing with 200 mg and 3
mg/kg every 12 hours, respectively, mean AUCs
in poor metabolizers and heterozygous extensive
metabolizers were approximately 4- and 2-fold
higher, respectively, than those of extensive
metabolizers.  The high blood concentrations of
voriconazole observed in poor metabolizers may
increase the magnitude of their drug interactions;
close monitoring of plasma concentrations may
be required in these individuals.41 Furthermore,
CYP2C9 expresses polymorphism, which, if
expressed, is associated with reduced enzymatic
activity.  The polymorphism is most prevalent
among Caucasians, less frequent among African-
Americans, and absent in Asians.  The magnitude
of interactions with CYP3A4 substrates varies,
ranging from no interaction (indinavir) to large
increases in exposure (sirolimus).
By contrast, fluconazole is only slightly
lipophilic and highly water soluble.  It is well
absorbed orally and less prone to drug inter-
actions than other drugs, particularly in the
intestine.38, 39 Drugs that interact with
fluconazole or voriconazole are substrates of
CYP2C9, CYP2C19, or CYP3A4.  The CYP-
mediated interactions with fluconazole are often
dose dependent.  Because fluconazole has linear
and predictable pharmacokinetics, these
interactions may be avoided or minimized by
using the lowest effective dose.
Posaconazole, an azole recently approved by
the U.S. Food and Drug Administration, is active
against a broad spectrum of fungi, including
Aspergillus and Candida species and Zygomycetes.
In vitro studies demonstrated that posaconazole
is an inhibitor but not a substrate of hepatic (but
not total) CYP3A425 and that it is both a substrate
and an inhibitor of P-gp.  This observation
suggests that it may have a drug-interaction
profile similar to that of other azoles.  In
addition, posaconazole undergoes glucuronidation by
uridine 5′-diphosphate–glucuronosyltransferase
enzymes.42
All five azoles inhibit CYP3A4 but with various
potencies.  Ketoconazole is the most potent
inhibitor, followed by itraconazole and
voriconazole (roughly equipotent), and then
fluconazole (Table 1).38, 41, 43, 44 The relative
inhibitory potency of posaconazole is not well
described at this time.  Its in vitro Ki values have
not been published, and the few clinical trials of
CYP3A4 substrates have been reported mainly in
abstract form.24, 25, 45 Differences in relative
potency translate into various degrees of
interaction when each of the azoles is combined
with a CYP3A4 substrate (as discussed later).
In clinical practice, fluconazole is the most
commonly used agent followed by voriconazole,
itraconazole, and, finally, ketoconazole.
Although new azoles have widely replaced
ketoconazole, its drug interactions with immuno-
suppressants are important because it is the most
potent inhibitor and because it represents an
important model for drug-drug interactions.
Metabolism of Cyclosporine, Tacrolimus, and
Sirolimus
Both intestinal and hepatic CYP3A4 metabolize
all immunosuppressants.  Cyclosporine
undergoes substantial presystemic metabolism;
its oral bioavailability ranges from 30–70%.
Tacrolimus is available as oral and parenteral
formulations.  Its oral absorption is incomplete
and variable, with an oral bioavailability of
10–30%.46 Sirolimus is available as an oral
solution and tablets, both of which have wide
interpatient and intrapatient variability in oral
absorption.  Although the oral bioavailability of
sirolimus is not known precisely, it has been
estimated to be about 15%.47
Cyclosporine, tacrolimus, and sirolimus are
substrates of CYP3A4 and both substrates and
inhibitors of P-gp.  As a consequence, they have
an immense potential for clinically significant
drug-drug interactions that result in increased
1736
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plasma concentrations of immunosuppressants,
excessive immunosuppression, and toxicity.
Because more than 50% of the hepatic
metabolism of cyclosporine, tacrolimus, or
sirolimus involves CYP3A4, drug interactions
resulting in complete induction or inhibition of
CYP3A4 are expected to lead to clinically
significant pharmacokinetic drug interactions.28
Because the correlation between dose and
plasma concentrations is poor, with wide
variability in interindividual and intraindividual
pharmacokinetics, and because many of the
adverse effects of immunosuppressants (especially
nephrotoxicity) are dose and plasma concen-
tration related, close monitoring of plasma
concentrations is necessary to guide dosage
adjustments, to minimize dose-related toxicity,
and to maximize efficacy.17, 28, 46–48
In clinically administered dosages, cyclosporine
appears to exert an inhibitory effect on P-gp
more potent than that of tacrolimus or
sirolimus.26 Although nephrotoxicity is a well-
recognized, concentration-dependent adverse
effect of cyclosporine and tacrolimus, the
relationship between plasma concentrations and
neurotoxicity is hypothetical.  Some have
proposed that cyclosporine- or tacrolimus-
induced inhibition of P-gp in the brain facilitates
the distribution of immunosuppressants in the
central nervous system, increasing concen-
trations of immunosuppressants in brain tissue.28
However, plasma concentrations of sirolimus
have not been correlated with any of its
documented adverse events.47
Drug Interactions Between Azoles and
Cyclosporine
Key steps in the metabolism of immuno-
suppressants are accomplished by CYP3A4.
Azoles inhibit this enzyme, decreasing metabolism,
increasing serum concentrations of immuno-
suppressants, and raising the potential for
immunosuppressant-induced toxicity (particularly
renal), overimmunosuppression, and oppor-
tunistic infections.8 Yet, the degree of inhibition
of CYP3A4 by individual azoles varies, and drug
interactions with immunosuppressants are best
described as an agent-specific rather than class
effect for all agents in the class.
Ketoconazole
Among drug interactions between immuno-
suppressants and azoles, the interaction between
cyclosporine and ketoconazole is the best
studied.  As the most potent CYP3A4 inhibitor of
the azoles and an inhibitor of P-gp, ketoconazole
and its concomitant administration with
cyclosporine increases the AUC of cyclosporine
almost 3-fold, allowing for cyclosporine dosage
reductions of 70–80%.49 The magnitude of this
interaction becomes fully apparent days to weeks
after the addition of ketoconazole to cyclosporine.
The interaction resolves 7–10 days after
ketoconazole is discontinued.50
Fluconazole
Fluconazole is a less potent inhibitor of
CYP3A4 than ketoconazole, itraconazole, or
voriconazole, and it is not an inhibitor of P-gp.12
Fluconazole inhibition of CYP3A4 appears to be
dose dependent, and interactions with cyclo-
sporine are generally important only with doses
of at least 200 mg/day.  Although early reports of
fluconazole and cyclosporine coadministration
suggested a lack of interaction, later reports
noted that administration of oral fluconazole 200
mg/day for 14 days doubled the AUC for
cyclosporine.51 Whether fluconazole 800–1200
mg/day, which is often used to treat invasive
candidal infections, further increases the AUC is
unknown.
Itraconazole
Itraconazole inhibits intestinal and hepatic
CYP3A4-mediated metabolism of cyclosporine.
Its effect on cyclosporine pharmacokinetics
varies.  Some, but not all, patients had elevated
cyclosporine concentrations during concomitant
administration of itraconazole.50 Itraconazole
generally doubles cyclosporine trough concen-
trations.  Inhibitory effects of itraconazole on
CYP3A4 metabolism of immunosuppressants
persist for several weeks after itraconazole is
discontinued because of its long half-life and its
pharmacologically active metabolites.38, 39
Voriconazole
Data regarding the interaction between
voriconazole and cyclosporine are somewhat
limited.  In kidney transplant recipients whose
condition was stabilized for at least 4 weeks with
individualized regimens of twice-daily cyclo-
sporine, the addition of oral voriconazole 200 mg
twice/day to oral cyclosporine 150–375 mg/day
increased the mean AUC for cyclosporine 1.7-
fold.  Because of these findings, the authors
suggested that the daily dose of oral cyclosporine
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be decreased 50% when voriconazole therapy is
started.40, 52 However, in patients who withdrew
from the study, trough concentrations of
cyclosporine increased as much as 3-fold.52
Posaconazole
In four heart transplant recipients, the dose of
cyclosporine was reduced 0–29% after the
addition of oral posaconazole 200 mg twice/day
for 10 days.  This outcome suggested that low
doses of posaconazole, similar to fluconazole, did
not substantially inhibit CYP3A4.25
Drug Interactions Between Azoles and
Tacrolimus
Drug interactions involving tacrolimus are less
well characterized in terms of their mechanism,
onset, potency, and clinical relevance than those
with cyclosporine.  The in vitro data are derived
from studies performed in various species (rat,
human, pig) and tissues (liver, small intestine,
gastrointestinal mucosa).  All demonstrated
differing magnitudes of azole inhibition of
CYP3A4-mediated metabolism of tacrolimus in
the liver and gastrointestinal tract.50 Available in
vitro data are poorly predictive of clinical results
in humans, and few controlled drug trials have
addressed this issue.28
Ketoconazole
The addition of oral ketoconazole 200 mg/day
to the regimen of a patient whose condition was
stabilized with tacrolimus prompted a reduction
in tacrolimus doses by as much as 80%.53 The
interaction was observed within 1 day after the
oral ketoconazole was started and persisted for
about 7 days after it was discontinued.  Despite a
preemptive decrease in the tacrolimus dosage by
45% when ketoconazole was begun, tacrolimus
plasma concentrations became supratherapeutic.
Fluconazole
Researchers investigated the interaction
between low-dose oral fluconazole 100 mg/day
for 7 days and oral tacrolimus in a prospective
randomized study of 19 renal allograft recipi-
ents.54 Within 5 days of the start of fluconazole,
doses of tacrolimus were decreased substantially.
The investigators concluded that a tacrolimus
dose equivalent to 60% of the initial dose (i.e., a
40% reduction in the dose of tacrolimus) was
appropriate during coadministration with
fluconazole.  Further dose reductions of
tacrolimus are presumably needed with doses of
fluconazole higher than this; however, this
possibility has not been evaluated.  Other
researchers reported that, after fluconazole was
discontinued, 9 days were required for evidence
of the drug interaction to resolve.55
Itraconazole
Specific data regarding the interaction between
itraconazole and tacrolimus are limited to
retrospective studies and case reports.  Several
investigators demonstrated that, with the
addition of oral itraconazole 200–400 mg/day to
tacrolimus, a 50–66% decrease in the dose of
tacrolimus was needed.56–58 The long half-life of
itraconazole prolonged the inhibition of
tacrolimus metabolism.  A report of a kidney
transplant recipient described an interaction
between oral itraconazole 100 mg twice/day and
tacrolimus.56 The onset of the interaction was
apparent less than 2 days after the start of
itraconazole.  Despite the discontinuation of
itraconazole after 5 days of therapy, the
interaction persisted for an additional 7 days, and
a 50% reduction in the dose of tacrolimus was
required.  Itraconazole 600 mg given orally
twice/day increased tacrolimus trough concen-
trations nearly 5-fold, highlighting the dose-
dependent inhibition and nonlinear pharmaco-
kinetics observed with this agent.57
Voriconazole
Among healthy volunteers who had received
oral voriconazole 400 mg twice/day for 1 day
followed by 200 mg twice/day for 6 days, a single
oral dose of tacrolimus 0.1 mg/kg tripled the
AUC for tacrolimus.40, 59 Given these findings,
the manufacturer of voriconazole recommends
reducing the daily dose of tacrolimus to 33% of
the initial dose (i.e., 66% reduction) when it is
used in combination.40 However, in a clinical
study of liver transplant recipients, trough
concentrations of tacrolimus during concomitant
oral administration of voriconazole 200 mg
twice/day increased nearly 10-fold in the first
subject, whose condition had been previously
stabilized with tacrolimus 2 mg/day.
The investigators had previously performed an
in vitro study in human liver microsomes in
which the concentration of voriconazole required
to inhibit tacrolimus metabolism by 50% was
10.4 ± 4.3 µg/ml.  The inhibition was concen-
tration dependent.  At concentrations of
voriconazole 5-, 10-, and 50-fold higher than
1738
AZOLE-IMMUNOSUPPRESSANT DRUG INTERACTIONS  Saad et al
those of tacrolimus, tacrolimus metabolism was
inhibited by 20%, 53%, and 76%, respectively.
Because typical maximum and trough serum
concentrations of voriconazole clinically
achieved after oral dosages of 200 mg twice/day
are 2.12–4.8 and 1.4–1.78 µg/ml, respectively, the
investigators expected an in vivo interaction of
50% or less.  The magnitude of the in vivo
interaction appeared to be greater than that
predicted by using the in vitro data.  They
hypothesized that high voriconazole concen-
trations in the gastrointestinal tract inhibited
intestinal CYP3A4 metabolism of tacrolimus,
similar to the interaction observed with
ketoconazole and tacrolimus.23
Posaconazole
Tacrolimus AUCs increased 4.5-fold with the
addition of oral posaconazole 400 mg twice/day
for 8 days.24 Of note, the interaction of
posaconazole with tacrolimus was greater than
that observed with cyclosporine, perhaps because
a relatively high dose of posaconazole was used.25
Drug Interactions Between Azoles and
Sirolimus
Ketoconazole
In healthy subjects, the addition of oral
ketoconazole 200 mg/day for 10 days to oral
sirolimus 5 mg/day decreased the oral clearance
of sirolimus by 90%, similar to its effect on
tacrolimus.60 These findings were confirmed in a
prospective study in six kidney transplant
recipients.61 However, careful monitoring and
dosage adjustment allowed investigators to
maintain appropriate plasma concentrations of
sirolimus.
Fluconazole
To our knowledge, no randomized studies have
been performed to assess the interaction between
fluconazole and sirolimus, and interactions have
largely been implied from observations between
azoles and other CYP3A4 or P-gp substrate
drugs, such as cyclosporine and tacrolimus.
However, the management of drug interactions
involving sirolimus may be complicated, even
during the coadministration of weak CYP3A4
inhibitors such as fluconazole.  One report
describes a kidney transplant recipient who
began sirolimus therapy on day 5 after
transplantation and oral fluconazole 200 mg/day
on day 25 after transplantation.62 Despite a
preemptive reduction in the dosage of sirolimus
from 4 to 3 mg/day on day 26 and an additional
reduction to 2 mg/day on day 30, the trough
concentration of sirolimus almost doubled by day
29 and tripled by day 32.
Voriconazole
The effect of voriconazole on the pharmaco-
kinetics of sirolimus is even more pronounced
than its effect on tacrolimus.  In a single-blinded,
randomized, placebo-controlled, two-period
crossover study of healthy subjects, oral
voriconazole 400 mg twice/day for day 1
followed by 200 mg twice/day for 8 days
increased the AUC of sirolimus (administered as
a 2-mg single oral dose on day 4) by a mean of
11-fold.40 Based on these findings, the
coadministration of voriconazole and sirolimus is
contraindicated.  However, in a recent case series
in eight patients whose sirolimus dose was
initially reduced by 90%, concomitant
administration of voriconazole and sirolimus for
a median of 33 days (range 3–100 days) resulted
in trough sirolimus levels similar to those
obtained before the administration of
voriconazole.63 No obvious, clinically significant
toxicity from either drug was observed.  Serious
adverse events were observed in two patients in
whom sirolimus dosage was not adjusted during
voriconazole administration.
Other Azoles
To date, no data are available regarding drug-
drug interactions between itraconazole or
posaconazole and sirolimus.
Effect of Intravenous versus Oral
Administration on Drug Interactions Between
Immunosuppressants and Azoles
Because CYP3A4 is expressed in the gastro-
intestinal tract wall and in the liver, inhibition of
CYP3A4 by azoles can occur at both sites.
Therefore, inhibition of CYP3A-mediated
metabolism of immunosuppressants is more
pronounced when the immunosuppressant is
administered orally than when it is given
intravenously.  Dual cooperativity of CYP
enzymes and P-gp in the gastrointestinal tract
contributes to remarkable differences in the oral
bioavailability of immunosuppressants observed
with ketoconazole versus fluconazole.  Because
immunosuppressants are substrates of P-gp and
because ketoconazole (but not fluconazole)
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inhibits P-gp, ketoconazole inhibition of P-
gp–mediated immunosuppressant efflux
increases the oral bioavailability of cyclosporine
more than fluconazole.  For example, the
administration of oral ketoconazole 200 mg/day
to five healthy subjects increased the oral and
hepatic bioavailabilities of cyclosporine 2.6- and
1.2-fold, respectively.64 Intravenous administration
of fluconazole 400 mg/day, a less potent CYP3A4
inhibitor than ketoconazole, reduced the
clearance of intravenously administered
cyclosporine by only 21%.65 Similar effects were
observed with oral tacrolimus.65–68 The
administration of oral ketoconazole doubled the
oral bioavailability of tacrolimus, whereas the
addition of intravenous fluconazole reduced
tacrolimus clearance by only 16–20%.
Recommendations for the Clinical Management
of Drug Interactions Between
Immunosuppressants and Azoles
Transplant recipients generally receive
numerous drugs, many of which induce, inhibit,
or are metabolized by CYP3A4 or utilize the P-gp
transport system.  Therefore, assessment and
management of drug interactions in this
population are complex, and the application of
generalized recommendations or guidelines in
these patients is difficult.  Reliable data are
lacking, and clinicians should use caution when
applying recommendations.
First, the practice of using in vitro and in vivo
scaling procedures to predict in vivo effects of
coadministered CYP inhibitors on drug
interactions is limited.  Although in vitro studies
provide useful screening tools and a rationale for
in vivo human investigations, human data should
be used whenever possible.17
Second, dosages of immunosuppressants may
need to be adjusted.  Table 2 provides recom-
mended dosage reductions of immunosuppres-
sants during concomitant therapy with immuno-
suppressants and azoles.24, 25, 40, 69–71 Although the
purpose of Table 2 is to suggest dosage adjust-
ments, interpatient variability can substantially
affect the occurrence, magnitude, and clinical
significance of these drug interactions.
Third, although enzyme inhibition is observed
immediately after the first dose of an inhibitor is
administered, minimal data are available
regarding the duration of inhibition after its
discontinuation.  The half-life of the inhibitor
and its protein binding can affect the duration of
inhibition.  In general, after an azole is discon-
tinued, a mean of 7–10 days is required for
concentrations of immunosuppressants to return
to baseline values.
Fourth, plasma concentrations of immuno-
suppressants should be monitored at the start of
therapy, throughout combined use, and, most
important, after concomitant azole therapy is
discontinued.
Fifth, recommendations in the literature suggest
preemptive dosage reductions of immuno-
suppressants when an azole is added.  However,
most lack validity.  Therefore, they are not the
standard of practice among transplant clinicians
who are concerned about an increased risk of
rejection in patients prescribed preemptive
dosage reductions of immunosuppressants
during concomitant therapy with azoles.
Additional studies are needed to assess the
validity and clinical outcomes of preemptive
dosage reduction.
Additional Factors Affecting Drug Interactions
Both drug- and patient-related factors help
determine the susceptibility to potential drug
interactions.28 Factors such as genomic
variability, sex, ethnicity, and disease states that
alter plasma drug concentrations can affect the
magnitude and clinical significance of drug
interactions.17 The effect of wide interpatient
variability in the absorption, distribution,
metabolism, and clearance of immuno-
suppressants on the magnitude and clinical
significance of drug interactions cannot be
overemphasized.28, 47
Sex-related differences can influence the
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Table 2.  Recommended Percentage Dose Reductions of
Immunosuppressants During Concomitant Azole
Therapy24, 25, 40, 69–71
Azole Cyclosporine Tacrolimus Sirolimus
Ketoconazole 70–80 50–60 80–90
Fluconazole 21–50a 40b 50–70c
(≥ 200 mg/day)
Itraconazole 50–60 50–60 No data
Voriconazole 50 66d 90e
Posaconazole 0–30f 75–80f, g No datag
aExtent of interaction depends on the route of administration of
cyclosporine (see text).
bBased on studies of low-dose fluconazole 100 mg/day.
cBased on limited data (see text).
dVariable (see text).
eUsed in clinical practice.  Coadministration is contraindicated
according to the manufacturer (see text).
fBased on limited data (see text).
gAt the time of writing.
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magnitude of drug interactions between azoles
and immunosuppressants.28 Tacrolimus
pharmacokinetics were compared in 11 male and
eight female kidney transplant recipients with
and without the concomitant use of
ketoconazole.  The coadministration of oral
ketoconazole and intravenous tacrolimus
decreased tacrolimus clearance significantly more
in the female patients than in the male patients.
When both drugs were administered orally, a
significantly greater increase in absolute
bioavailability was observed in the female
subjects.68 Researchers theorize that these sex-
related differences could result from lower
metabolic capacity of the intestinal microsomes
in male subjects than in premenopausal female
subjects or from high P-gp activity in female
subjects that increases the efficiency of CYP-
mediated metabolism.28
Ethnicity affects cyclosporine pharmaco-
kinetics because hepatic CYP3A4 activity is
increased in some groups.28 The oral bioavail-
ability of tacrolimus was significantly lower in
African-American healthy volunteers and kidney
transplant recipients than other subjects perhaps
because of differences in intestinal P-gp and
CYP3A4 metabolism rather than differences in
hepatic metabolism.28, 72 Differences in the oral
bioavailability of tacrolimus result in differences
in the dose response.  Among kidney transplant
recipients, African-Americans require daily
doses of tacrolimus 37% higher than those
needed by Caucasians to achieve similar plasma
concentrations.73
Finally, in addition to factors just discussed,
inflammatory small-bowel disease, cirrhosis,
stress, infections, poor nutritional status, and
increased age decrease the amount and activity of
CYP3A4 present in tissues.
Advantages of Drug Interactions
Although drug-drug interactions are usually
considered undesirable events, they can be
beneficial.  Therapy with immunosuppressants
can be cost-prohibitive.  Reduction of daily doses
of immunosuppressants due to ketoconazole-
induced inhibition of their clearance can reduce
therapeutic doses of the immunosuppressants by
70–85%.  This drug combination has proved to
be well tolerated and effective, and it is consid-
ered less costly than cyclosporine monotherapy.74
Investigators who reviewed the clinical and
cost-saving potential of cyclosporine drug
interactions concluded that ketoconazole
appeared to be the best candidate for reducing
the financial burden of long-term immuno-
suppressive therapy without sacrificing patients’
well-being.74 A 5-year study of patients receiving
combined ketoconazole and cyclosporine showed
no clinical difference in outcomes, including
renal function, hepatic function, blood pressure,
use of antihypertensive drugs, or patient or graft
survival.73 The combined use of ketoconazole
and cyclosporine could decrease the yearly per-
patient cost of cyclosporine by approximately
$3750, which could translate to a national annual
savings of more than $100 million in patients
undergoing solid organ transplantation.  Other
reported advantages were decreased frequencies
of infections and episodes of acute rejection in
patients who received ketoconazole and
cyclosporine versus placebo and cyclosporine.74
A 10-year follow-up study of transplant
patients receiving cyclosporine alone or
combined with ketoconazole confirmed the
continuity of cyclosporine dosage reduction and
cost savings.75 Clinical benefits associated with
combination therapy included similar frequencies
of acute-rejection episodes in both groups,
although the frequency and rates of unfavorable
responses to therapy were higher in the control
group.  The frequency of chronic allograft
nephropathy was also significantly lower in the
ketoconazole group than in the control group;
this difference was sustained after 10 years.
However, data have suggested that the use of
ketoconazole to reduce the dosage of cyclo-
sporine may compromise long-term graft survival
and increase the risk of late acute or chronic
rejection.  A potentially detrimental effect of
ketoconazole on graft survival might occur
because of the delayed and decreased maximum
concentrations and because of the flattened or
unpredictable absorption of cyclosporine
observed during concomitant therapy.76 In the
absence of definitive answers and given the
conflicting information, the benefits of
combination therapy in terms of infections and
graft survival must be investigated further.
Few clinical trials have been conducted to
evaluate the economic or clinical outcomes
associated with the combined use of fluconazole
and cyclosporine.  A 3-month course of cyclo-
sporine combined with fluconazole versus
clotrimazole resulted in an estimated drug
savings of $900/patient, with a significantly
decreased rate of fungal infections in the group
receiving fluconazole.77
Itraconazole coadministration with cyclosporine
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decreased the mean dose requirement for
cyclosporine by 50% and resulted in an mean
cost savings of $233/patient/month.74 Similar
cost savings were reported with the combined
use of ketoconazole and sirolimus.61 The cost of
sirolimus 2 mg/day was $625/month compared
with $86 for the combination of sirolimus 0.25
mg/day and ketoconazole 200 mg/day.
The cost of tacrolimus was also reduced by
57% when tacrolimus was used concomitantly
with ketoconazole.  Additional benefits included
a decrease in the total days of hospitalization,
fungal skin infections, and rate of acute rejection,
and a substantial improvement in graft
function.78
Reports suggest potential economic benefits of
fluconazole or itraconazole combined with
immunosuppressants.  However, ketoconazole
remains the drug of choice for this indication
because it is the most extensively studied azole
and the least expensive and most potent
inhibitor.  Because only low doses of keto-
conazole are needed to achieve major reductions
in dosages of immunosuppressants, fewer adverse
effects and similar or improved economic
benefits can be achieved with ketoconazole than
with other azoles.
Drug Interactions Between Azoles and
Investigational Immunosuppressants
Everolimus is an investigational immuno-
suppressant that is structurally similar to
sirolimus and that is intended to be given in
combination with cyclosporine after solid organ
transplantation.  Because everolimus is a
substrate of P-gp and CYP3A4, CYP3A5, and
CYP2C8, a number of drug-drug interactions
with azoles can occur.  Although the adminis-
tration of fluconazole has no substantial effect on
the pharmacokinetics of everolimus, adminis-
tration of itraconazole decreases its clearance by
74%.79
In subjects administered oral ketoconazole 200
mg twice/day for 8 days, a single 1-mg dose of
everolimus coadministered with ketoconazole on
day 4 increased the AUC 15-fold.  The inter-
action was evident 24 hours after the adminis-
tration of everolimus, and plasma concentrations
of everolimus were detectable until day 24.  The
authors concluded that the concomitant use of
ketoconazole and everolimus should be avoided
if possible.80 This result emphasizes the need to
monitor drug concentrations and to further
evaluate drug interactions with everolimus.
Conclusion
Drug interactions between azoles and
immunosuppressants are agent specific and
depend on the potency of the azole inhibition of
CYP and P-gp, the plasma concentrations of each
agent, the drug formulation, and interpatient
variability.  Trough concentrations of cyclosporine,
tacrolimus, and sirolimus must be monitored,
and their dosages must be adjusted accordingly
when an azole is added or discontinued.
Clinicians should monitor patients for toxicity
and loss of efficacy a few days to a week after
starting and 7–10 days after discontinuing
combination therapy.
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